BIO as reported
Bio-Rad Laboratories, Inc. reported $2.59B of revenue over the trailing twelve months, +1.9% on the year before. 11 reported series are charted on this page, each one as filed.
$2.59B
Revenue, trailing twelve months · to Q1 2026 · +1.9% against the twelve months before
- Net Income
- $169M
Net Income · −108% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $357M
Free Cash Flow · +0.48% year on year · trailing twelve months to Q1 2026
- Op Margin
- 2.6%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $2.59B | +1.9% | Q1 2026 |
| Net Income | $169M | −108% | Q1 2026 |
| EPS | $5.81 | −108% | Q1 2026 |
| Gross Margin | 52% | n/a | Q1 2026 |
| Op Margin | 2.6% | n/a | Q1 2026 |
| Net Margin | 2.8% | n/a | Q1 2026 |
| ROE | 1.8% | n/a | Q1 2026 |
| ROA | 1.3% | n/a | Q1 2026 |
| ROIC | 1.6% | n/a | Q1 2026 |
| Free Cash Flow | $357M | +0.48% | Q1 2026 |
| P/E | 67.0 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Bio-Rad Laboratories, Inc. (BIO) - Revenue & ProfitRevenue & ProfitBio-Rad Laboratories, Inc. (BIO)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Medical Devices
Ranks #27 of 35 by Smart Score